Boston, MA · Founded 2019 · Privately Held (backing)
Developer of an artificial intelligence-based neurotechnology platform designed for accelerating the clinical development of therapeutics targeting brain health. Beacon Biosignals is based in Boston, MA and was founded in 2019. It was valued at $334 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $127 million across 2 recorded rounds; the latest was a $103 million later-stage round in Oct 2025.
PMV mark · valuation
$334.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$126.9M
Last round
Later Stage VC
Oct 2025
No prints on record
No secondary trades in Beacon Biosignals shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Beacon Biosignals with a free account
·The complete investor list: 20 names
·Watch Beacon Biosignals: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Beacon Biosignals stock.
